Clinical Trial

Safety and Preliminary Efficacy of TSHA-102 Gene Therapy in Pediatric Females Aged >2 to <4 Years With Rett Syndrome

Name: Safety and Preliminary Efficacy of TSHA-102 Gene Therapy in Pediatric Females Aged >2 to <4 Years With Rett Syndrome — clinical trial record (NCT07480564)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: ASPIRE

Recruiting Phase 3

View on ClinicalTrials.gov →

Summary

The primary objectives of this study are to evaluate the safety, tolerability and preliminary efficacy of a single intrathecal (IT) dose of TSHA-102 in pediatric females with typical Rett syndrome.

Protocol Amendment History 1 change

critical Recruitment opened 2026-05-23

Trial Details

NCT Number	NCT07480564
Lead Sponsor	Taysha Gene Therapies, Inc.
Conditions	Rett Syndrome
Enrollment	3 participants
Start Date	2026-05-08
Primary Completion	2031-06 (estimated)
Study Completion	2031-06 (estimated)
Updated on ClinicalTrials.gov	2026-05-22